| dc.contributor.author | Kater, Arnon | |
| dc.contributor.author | Panagiotis, Panayiotidis | |
| dc.contributor.author | Aktan, Melih | |
| dc.contributor.author | Arslan, Onder | |
| dc.contributor.author | Demirkan, Fatih | |
| dc.contributor.author | Enggaard, Lisbeth | |
| dc.contributor.author | Forconi, Francesco | |
| dc.date.accessioned | 2020-06-21T12:18:11Z | |
| dc.date.available | 2020-06-21T12:18:11Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1042-8194 | |
| dc.identifier.issn | 1029-2403 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/10129 | |
| dc.description | WOS: 000534385400082 | en_US |
| dc.description.abstract | … | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Taylor & Francis Ltd | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis | en_US |
| dc.type | conferenceObject | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 61 | en_US |
| dc.identifier.startpage | 113 | en_US |
| dc.identifier.endpage | 115 | en_US |
| dc.relation.journal | Leukemia & Lymphoma | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
